Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets. The 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift, reimbursement timelines extend, and programmes scale globally, organisations must make more decisions, earlier, and with greater consequence. This is the only European forum dedicated to the operational reality of early access - bringing together 140+ leaders across Medical Affairs, Access, Regulatory, Clinical Operations, and Supply to share how programmes are being designed, adapted, and delivered in practice. Whether you are building your first programme, scaling across regions, or managing a global access portfolio, this is your opportunity to benchmark your approach, challenge your assumptions, and leave with the insight needed to make smarter decisions and deliver earlier, sustainable access for patients in 2026 and beyond. Solution Provider Pricing - Conference + Pre-Conference Workshop Day: GBP 4497.00 Speakers: Ahmed Hnoosh Director - Worldwide Health Economics and Outcomes Research Bristol Myers Squibb, Ann Watkins Associate Director, Medical Affairs, EUR/International Jazz Pharmaceuticals, Antoine Robert Global Post-Trial Access Lead Sanofi, Cassandra Slader, Global Head of Managed Access Programs UCB, Catherine Singfield, Senior Director and Head of Medical, Evidence Optimisation and Managed Access Programmes Team, Jazz Pharmaceuticals, Dan Weeks Head of Global Access Mechanisms Biogen, Jason Cameron Associate Director Bristol Myers Squibb, Karolina Gliwska-Szałankiewicz Director Evidence Operations, Oncology Business Unit Medical Evidence AstraZeneca, Micheal Al-Rachid Associate Director, Commercial Operations and Business Intelligence Eisai Co., Ltd., Olga Andreeva Head of Expanded Access Center of Excellence Novo Nordisk, Pedro Franco Senior Director and Head of Europe Global Regulatory and Scientific Policy, Merck KGaA, Ozlem Yilmaz Head, Medical Affairs (Growth Markets; Central Eastern Europe and Middle East and North Africa) Eisai Co., Ltd., Rachel Harrison Director - Pre-Approval, Post-Trial Access Programs, Medical Affairs and Evidence Generation Argenx, Ramona Reichenbach Head Managed Access and Medical Policy Novartis AG, Vilem Guryca Director, Expanded Access, Global Medical Affairs BeOne Medicines, Archit Kalra Chief Executive Officer Kalevala Therapeutics, Inc., Arzu Mulayim Senior Medical Director, Mid Sized European Countries ACADIA Pharmaceuticals Inc., Ceren Guzelalp Director, Early Access and Patient Support, Europe ACADIA Pharmaceuticals Inc., Claire Ramer Associate Director, Global Medical Affairs Operations, Deciphera Pharmaceuticals, Inc, Clare Baker Senior Director, Head of Medical

Description supplied by the event organiser.